Home Newsfeeds Benchmark Downgrades Emergent BioSolutions to Hold

Benchmark Downgrades Emergent BioSolutions to Hold

Benchmark analyst Robert Wasserman downgrades Emergent BioSolutions (NYSE:EBS) from Buy to Hold.

byBenzinga Newsdesk

November 10, 2022

1 minute read

Benchmark analyst Robert Wasserman downgrades Emergent BioSolutions (NYSE:EBS) from Buy to Hold.

Commvault Expects Q4 Revenue of $210M-$214M Vs $210.18 Est, FY24 Revenue of $826M-$830M Vs $817.34M Est

By Benzinga Newsdesk

January 30, 8:52 AM

Financial Outlook for Fourth Quarter and Full Year Fiscal 2024 - We are providing the following guidance for the fourth quarter of fiscal year 2024: Total revenues are

CVLT

Vincerx Pharma’s Preclinical Data From Blood Cancer Candidate Shows Efficacy, Lower Toxicity

By Vandana Singh

April 19, 11:25 AM

Vincerx Pharma Inc (NASDAQ:VINC) presented a poster of VIP924 preclinical data at the 2023 American Association for Cancer Research (AACR) Annual…

VINC

Virtus Investment Partners Increases Quarterly Common Stock Dividend From $0.65 To $1.90 Per Share

By Happy Mohamed

August 17, 8:08 AM

Sixth consecutive annual dividend increase Virtus Investment Partners, Inc. (NASDAQ:VRTS), which operates a multi-manager asset management business, today announced that its Board of Directors has approved a

VRTS

Heart Disease Drugmaker Esperion Therapeutics Reports Highest Revenue Yet, Stock Soars

By Vandana Singh

May 7, 10:20 AM

Esperion Therapeutics reports impressive Q1 revenues of $137.74 million, up 467% Y/Y, with EPS of $0.34, beating estimates. FDA approved expanded labels for NEXLETOL & NEXLIZET. Fiscal year 2024 revenue guidance: $225-$245 million.

ESPR

Benchmark Downgrades Emergent BioSolutions to Hold

Related Posts

Commvault Expects Q4 Revenue of $210M-$214M Vs $210.18 Est, FY24 Revenue of $826M-$830M Vs $817.34M Est

Vincerx Pharma’s Preclinical Data From Blood Cancer Candidate Shows Efficacy, Lower Toxicity

Virtus Investment Partners Increases Quarterly Common Stock Dividend From $0.65 To $1.90 Per Share

Heart Disease Drugmaker Esperion Therapeutics Reports Highest Revenue Yet, Stock Soars